Trials / Completed
CompletedNCT06113081
Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma: a Multicenter Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- Fondazione Italiana Linfomi - ETS · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to describe the clinical activity and safety profile of mogamulizumab at standard dose in the treatment of CTCL patients in real world setting
Detailed description
Mogamulizumab (anti-CCR4) has been recently approved and reimbursed in Italy for the treatment of Cutaneous T-cell lymphoma (CTCL) after 1 previous systemic treatment based on the favourable results of the MAVORIC clinical trial. To date, no real-world data on significant series of patients treated routinely with mogamulizumab in clinical practice are available. As real-life data are essential to confirm the preliminary evidence displayed in phase III trials, this study aims at describing the clinical activity and safety profile of mogamulizumab at standard dose in the treatment of CTCL patients in real world settings.
Conditions
- Cutaneous T Cell Lymphoma
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- Cutaneous T-Cell Lymphoma/Sezary Syndrome
Timeline
- Start date
- 2024-06-06
- Primary completion
- 2025-10-10
- Completion
- 2025-11-11
- First posted
- 2023-11-02
- Last updated
- 2025-12-24
Locations
21 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT06113081. Inclusion in this directory is not an endorsement.